Neuroinflammation and COVID-19
Нейровоспаление и COVID-19
2022-06-29
SCID: 54.1/uur47ezt
Discuss with AI
COVID-19 neuroinflammationSARS-CoV-2blood-brain barriercentral nervous systeminnate immunity
Figures from the paper
Abstract (AI)
Coronavirus disease 2019 (COVID-19) has caused a historic pandemic of respiratory disease. COVID-19 also causes acute and post-acute neurological symptoms, which range from mild, such as headaches, to severe, including hemorrhages. Current evidence suggests that there is no widespread infection of the central nervous system (CNS) by SARS-CoV-2, thus what is causing COVID-19 neurological disease? Here, we review potential immunological mechanisms driving neurological disease in COVID-19 patients. We begin by discussing the implications of imbalanced peripheral immunity on CNS function. Next, we examine the evidence for dysregulation of the blood-brain barrier during SARS-CoV-2 infection. Last, we discuss the role myeloid cells may play in promoting COVID-19 neurological disease. Combined, we highlight the role of innate immunity in COVID-19 neuroinflammation and suggest areas for future research.
Key Findings
1
COVID-19 causes neurological symptoms ranging from headaches to severe hemorrhages, both acutely and after the initial infection.
2
Current evidence does not support widespread SARS-CoV-2 infection of the central nervous system as the primary cause of neurological disease.
3
Imbalanced peripheral immune responses may disrupt central nervous system function during COVID-19.
4
Innate immune mechanisms, including potentially pathogenic myeloid-cell activity, are highlighted as drivers of COVID-19-associated neuroinflammation.
5
SARS-CoV-2 infection may dysregulate the blood-brain barrier, contributing to neuroinflammation and neurological symptoms.
Research Object
COVID-19 neurological disease and neuroinflammation in patients with SARS-CoV-2 infection
Research Subject
Immunological mechanisms of COVID-19 neurological disease, including peripheral immune imbalance, blood-brain barrier dysregulation, and myeloid-cell-mediated effects
Publication Details
Publication Date
2022-06-29
Journal
Publisher
ISSN
Cited by
125
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis2004
The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier2020
COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital2021
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-22022
Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates2022